Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07321197 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC)

Study acronym: RECLND
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoint(s) modified Recruitment opened · Study sites: 0 to 1 · Start date changed from estimate of Jan 1, 2026 to Sep 1, 2025 · 4 morev2 Show 7 more changesShow less
    • Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 1, 2026 to Sep 1, 2025
    • Eligibility criteria revised
    • Secondary endpoints: 4 to 5
    • Study description expanded, about 13 words
    • Study title shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn if a more thorough lymph node removal surgery, called "Template Lymph Node Dissection," can help prevent cancer from returning and help patients live longer, compared to removing only a few enlarged lymph nodes, in patients with high-risk kidney cancer. The main questions it aims to answer are: Do patients who receive template lymph node dissection live longer without their cancer returning (Disease-Free Survival)? Do patients who receive template lymph node dissection live longer overall (Overall Survival)? Is the more extensive lymph node surgery as safe as the limited surgery? Researchers will compare the Template Lymph Node Dissection group to the Limited Node Resection group to see the effects on cancer control and safety. Participants will: Be randomly assigned to one of the two surgical groups. Undergo surgery to remove their kidney and the assigned lymph nodes. Attend regular follow-up visits with imaging scans (like CT or MRI) for the first 5 years after surgery to monitor if the cancer returns. Be followed for their overall survival status for up to 10 years.
Trial Details
NCT Number NCT07321197
Lead Sponsor Tianjin Medical University Second Hospital
Collaborators: Sun Yat-Sen University Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center, Tianjin Third Central Hospital
Conditions Renal Cell Carcinoma (Kidney Cancer)
Enrollment 220 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov